General description
Glimepiride is a class II biopharmaceutical second-generation sulfonylurea.
Application
Glimepiride has been used:
- as a hypoglycemic drug to test its anti-diabetic functionality in human umbilical vein cells (HUVECs)
- as a sulfonylurea ATP-sensitive potassium channel (KATP) channel inhibitor in breast cancer MDA-MB-231 cells
- in glucose-stimulated insulin secretion (GSIS) assays of neonatal islet-like cell clusters (NICCs) to test its effect on insulin secretion
Glimepiride is currently used to treat type 2 diabetes.
Biochem/physiol Actions
Glimepiride is a potent blocker of cardiac KATP channels activated by pinacidil with an IC50 of 6.8 nM.
Glimepiride reduces blood glucose levels by stimulating the pancreatic β cells to secrete insulin hormone. It interacts with a 65-kD protein associated with β cells.
Features and Benefits
This compound was developed by Sanofi Aventis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
- UPC:
- 51124503
- Condition:
- New
- Weight:
- 1.00 Ounces
- HazmatClass:
- No
- WeightUOM:
- LB
- MPN:
- G2295-250MG